Pfizer sides with Merck KGaA on PD-L1; AZ deal out for good?
This article was originally published in Scrip
Executive Summary
Pfizer and Merck KGaA's plans to jointly develop the latter's anti-PD-L1 drug is positive news for all in the field.
You may also be interested in...
Pfizer’s Avelumab Poised For Speedy Review By FDA
Avelumab could be the fourth PD-1/L1 inhibitor to reach the market now that the US FDA has accepted Pfizer’s and Merck KGaA’s BLA for priority review in the treatment of metastatic Merkel cell carcinoma.
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.